Monitoring Agency Report for the quarter ended 31 March 2025 in relation to the Initial Public Offer (IPO) of the Company
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sai Life Sciences Limited submitted the Monitoring Agency Report from Crisil Ratings Limited covering how the company used money raised from its December 2024 IPO. The total IPO size was Rs 3,042.62 crore, of which the fresh issue was Rs 950 crore and the offer for sale was Rs 2,092.62 crore. After deducting Rs 40.12 crore in issue expenses, net proceeds stood at Rs 909.88 crore. As of March 31, 2025, the company has utilized Rs 797.01 crore (about 88%), with Rs 112.88 crore still unutilized. The full Rs 720 crore earmarked for repayment of borrowings has been used, while Rs 77.01 crore out of the Rs 189.88 crore allocated for general corporate purposes has been spent — mostly on equipment and machinery (Rs 43.89 crore) and ordinary business expenses like salaries and utilities (Rs 28.06 crore). There is no deviation from the stated objects and no delay in implementation. The unutilized Rs 112.88 crore is parked in five SBI fixed deposits (Rs 250 crore each originally), the public offer account (Rs 23.41 crore), and the monitoring account (Rs 0.02 crore), earning 7.70% interest.
This is a routine compliance filing that confirms the company is using IPO funds as promised — primarily to clean up debt, with the balance being deployed progressively for general business needs. The idle funds are safely parked in bank fixed deposits earning reasonable returns, so there is no negative signal for shareholders. The report indicates disciplined use of capital with no red flags.